Reading the actual results (https://finance.yahoo.com/sectors/healthcare/articles/tovecimig-demonstrates-statistically-significant-benefit-113000084.html) it looks like the drug works, but “failed” in an secondary endpoint because of high crossover with other med, which is not entirely bad
Overall this 65% drop feels like an overreaction, did an LLM just read “failed” once in the release and decided to dump the stock?
[https://finance.yahoo.com/quote/CMPX/](https://finance.yahoo.com/quote/CMPX/)
